1. Home
  2. TRVI vs PRG Comparison

TRVI vs PRG Comparison

Compare TRVI & PRG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Trevi Therapeutics Inc.

TRVI

Trevi Therapeutics Inc.

SELL

Current Price

$12.50

Market Cap

1.8B

Sector

Health Care

ML Signal

SELL

Logo PROG Holdings Inc.

PRG

PROG Holdings Inc.

HOLD

Current Price

$29.38

Market Cap

1.6B

ML Signal

HOLD

Company Overview

Basic Information
Metric
TRVI
PRG
Founded
2011
2020
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Diversified Commercial Services
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
1.8B
1.6B
IPO Year
2019
2020

Fundamental Metrics

Financial Performance
Metric
TRVI
PRG
Price
$12.50
$29.38
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
11
7
Target Price
$28.18
★ $52.00
AVG Volume (30 Days)
★ 2.5M
543.2K
Earning Date
11-12-2026
10-28-2026
Dividend Yield
N/A
★ 1.85%
EPS Growth
★ 31.91
N/A
EPS
N/A
★ 1.80
Revenue
N/A
★ $2,409,223,000.00
Revenue This Year
N/A
$27.00
Revenue Next Year
N/A
$7.67
P/E Ratio
★ N/A
$16.81
Revenue Growth
★ N/A
N/A
52 Week Low
$9.82
$25.80
52 Week High
$20.22
$47.73

Technical Indicators

Market Signals
Indicator
TRVI
PRG
Relative Strength Index (RSI) 36.03 33.32
Support Level $11.70 $28.86
Resistance Level $13.55 $33.81
Average True Range (ATR) 0.66 1.07
MACD 0.13 0.23
Stochastic Oscillator 44.81 16.88

Price Performance

Historical Comparison
TRVI
PRG

About TRVI Trevi Therapeutics Inc.

Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, non-IPF interstitial lung disease, or non-IPF ILD, and refractory chronic cough, or RCC. Haduvio is an oral extended-release formulation of nalbuphine. The Company operates and manages its business as one reportable segment. Such a segment is the business of developing and commercializing the investigational therapy Haduvio.

About PRG PROG Holdings Inc.

PROG Holdings Inc is a financial technology holding company that provides transparent and competitive payment options to consumers. The company has two reportable segments: Progressive Leasing, an in-store, app-based, and e-commerce point-of-sale lease-to-own solutions provider; and Vive Financial (Vive), an omnichannel provider of second-look revolving credit products. The majority of the revenue of the company is earned through the Progressive Leasing segment.

Share on Social Networks: